R906289

DB19126InvestigationalSmall molecule

R906289 is under investigation in clinical trial NCT05308264 (Study of R289 in Participants With Lower-risk Myelodysplastic Syndromes (LR MDS)).

Mechanism: Pharmacologically active on Interleukin-1 receptor-associated kinase 4 and Interleukin-1 receptor-associated kinase 1
Curator reviewed
Formula / weight: C₂₅H₂₈F₂N₇O₆PS · 623.57 g/mol (avg)
Code names: R-289 · R-906289

Resolves to

Compound

Structure

InChIKeyZSSREAXVWYYKJC-ZCQHSFHSSA-NSMILESCCO[C@H]1CC[C@@H](CC1)N1C=C(NC(=O)C2=CSC(=N2)C2=CN(N=C2)C(C)OP(O)(O)=O)C(=N1)C1=NC(F)=CC=C1F

Targets

What you can answer from here — as of August 31, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with R906289, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.